Drugs / Inactivated Poliomyelitis Vaccine (Salk strains)
Inactivated Poliomyelitis Vaccine (Salk strains)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01056705 | Jul 2009 → May 2010 | poliomyelitis | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01510366 | Jan 2012 → Sep 2015 | poliomyelitis | Institute of Medical Biology, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated Poliomyelitis Vaccine (Salk strains) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01510366 ↗ |
| Modality | Vaccine | “Inactivated Poliomyelitis Vaccine (Salk strains)was manufactured by Sanofi Pasteur DAg contents /0.5ml/per dose were Type 1 40 DU,Type 2 8DU,Type 3 32DU.” NCT01056705 ↗ |
| Route | Intramuscular | “3 x 0.5ml intramuscular injections” NCT01510366 ↗ |